

The PAR2 inhibitor I-287 selectively targets $G\alpha_q$ and $G\alpha_{12/13}$ signaling and has anti-inflammatory effects

Charlotte Avet¹, Claudio Sturino^{2,4}, Sébastien Grastilleur³, Christian Le Guillou¹, Meriem Semache^{1,5}, Florence Gross^{1,5}, Louis Gendron³, Youssef Bennani^{2,6}, Joseph A. Mancini^{2,7}, Camil E. Sayegh^{2,8} & Michel Bouvier¹✉

Protease-activated receptor-2 (PAR2) is involved in inflammatory responses and pain, therefore representing a promising therapeutic target for the treatment of immune-mediated inflammatory diseases. However, as for other GPCRs, PAR2 can activate multiple signaling pathways and those involved in inflammatory responses remain poorly defined. Here, we describe a new selective and potent PAR2 inhibitor (I-287) that shows functional selectivity by acting as a negative allosteric regulator on $G\alpha_q$ and $G\alpha_{12/13}$ activity and their downstream effectors, while having no effect on $G_{i/o}$ signaling and β arrestin2 engagement. Such selective inhibition of only a subset of the pathways engaged by PAR2 was found to be sufficient to block inflammation *in vivo*. In addition to unraveling the PAR2 signaling pathways involved in the pro-inflammatory response, our study opens the path toward the development of new functionally selective drugs with reduced liabilities that could arise from blocking all the signaling activities controlled by the receptor.

¹Institute for Research in Immunology and Cancer, and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, Canada H3C 1J4. ²Vertex Pharmaceuticals (Canada), Inc., Laval, QC, Canada H7V 4A7. ³Département de Pharmacologie-Physiologie, Université de Sherbrooke, Centre de Recherche du CHU de Sherbrooke, Centre d'Excellence en Neurosciences de l'Université de Sherbrooke, Institut de Pharmacologie de Sherbrooke, Sherbrooke, QC, Canada J1H 5N4. ⁴Present address: Paraza Pharma, Inc., Saint-Laurent, QC, Canada H4S 2E1. ⁵Present address: Domain Therapeutics North America, Saint-Laurent, QC, Canada H4S 1Z9. ⁶Present address: AdMare BioInnovations, Saint-Laurent, QC, Canada H4S 1Z9. ⁷Present address: Vertex Pharmaceuticals Inc., Boston, MA 02210, USA. ⁸Present address: Ra Pharmaceuticals, Inc., Cambridge, MA 02140, USA. ✉email: michel.bouvier@umontreal.ca

The protease-activated receptors (PARs) family, which comprises four members (PAR1–4), represents an atypical group among G-protein-coupled receptors (GPCRs), as they are activated by proteases rather than by the binding of soluble ligands. PARs are activated by the proteolytic cleavage of their N-terminal region by proteases such as thrombin, trypsin, and others. This cleavage exposes a region of the N-terminal extracellular domain, “tethered ligand” (TL), which then binds to the extracellular loops and transmembrane (TM) domains of the PARs. This results in the stabilization of an active conformation of the receptor that induces intracellular signal transduction^{1,2}.

Among them, PAR2 is expressed in a wide range of cellular types, including endothelial, epithelial, immune, neuronal and smooth muscle cells, where it has been involved in multiple physiological and pathophysiological processes including nociception, cellular permeability, contractility, motility, proliferation, inflammatory responses, and cancers^{1,2}. PAR2 is activated mainly by trypsin-like serine proteases such as trypsin, mast cell tryptase, tissue kallikreins, and coagulation factors VIIa and Xa^{1,3–5}, but some proteases such as elastase or cathepsin-S have also been shown to cleave the receptor at non-canonical sites leading to a distinct activating sequence than the canonical TL and different signaling^{6–8}. Short synthetic peptides mimicking the TL sequences, also called activating peptides, such as SLIGKV-NH₂, SLIGRL-NH₂, or 2-furoyl-LIGRL-NH₂, can also directly activate PAR2 without proteolytic cleavage of its N-terminal extremity^{9–11}. In addition, a subset of activating peptides (e.g., 2f-LAAAAI-NH₂, Isox-Cha-Chg-NH₂, and Isox-Cha-Chg-Ala-Arg-NH₂) have been shown to promote the activation of only a subset of the signaling pathways engaged by PAR2; a concept known as functional selectivity or biased signaling¹². PAR2 has been shown to activate a wide variety of intracellular signaling pathways, including G-protein-dependent pathways leading to Ca²⁺ mobilization, inhibition of cAMP production, mitogen-activated protein kinase ERK1/2 activation, Rho activation, and G-protein-independent signaling through β arrestin1/2 recruitment^{1,2}.

Mounting evidence suggest that PAR2 plays an important role in mediating some of the inflammatory and pain responses associated with immune-mediated inflammatory diseases (IMIDs), a collection of highly disabling conditions resulting from the pathological activation of inflammatory pathways. PAR2 activation results in the release of inflammatory cytokine and chemokine from keratinocytes, endothelial, and epithelial cells¹³. Moreover, the administration of PAR2-activating proteases and synthetic agonists in vivo induce inflammatory responses^{14–16}. Further, both in vitro and in vivo studies have demonstrated a role for PAR2 activation in tissue remodeling by promoting fibroblast and myofibroblast proliferation, and the secretion of growth factors such as connective tissue growth factor and extracellular matrix components including collagen¹⁷. In addition, PAR2 activation is implicated in cellular migration and has recently been shown to promote tumor growth and metastasis^{18–20}. Finally, using PAR2-deficient mice or blocking receptor activation using specific antibodies or antagonists such as GB88 revealed an important role for PAR2 activation in the pathophysiology of a variety of IMID, including asthma, chronic pain, rheumatoid arthritis, periodontitis, inflammatory bowel diseases, skin diseases, cancer, fibrotic diseases, and neurological disease²¹. Although currently available PAR2 antagonists act through a variety of mechanisms that can be leveraged to understand the impact of PAR2 blockade, the specific pathway(s) mediating PAR2-dependent inflammatory effects remains poorly defined.

In the present study, we report the signaling properties of I-287, a bicyclic heteroaryl derivative developed by Vertex Pharmaceuticals and described in the patent WO2016154075²². Using bioluminescence resonance energy transfer (BRET)-based assays

that allow direct monitoring of the engagement and activation of proximal signaling effectors (Supplementary Table 1), we first established the signaling repertoire of PAR2 triggered by trypsin and PAR2-activating peptides, and then established the functional selectivity of I-287 that leads to anti-inflammatory activity in vitro and in vivo. Taken together, our results demonstrated that blocking the activation of G_q and G_{12/13} without affecting the activation of G_{i/o} or the recruitment of β -arrestin is sufficient to blunt PAR2-mediated inflammatory responses.

Results

G-protein activation profile of PAR2. As only a few numbers of studies have clearly demonstrated the direct coupling of PAR2 to specific G α isoforms^{23–25}, we first established the profile of G α subunits activated by human PAR2 (hPAR2) using a BRET²-based assay platform in human embryonic kidney 293 (HEK293) cells. We took advantage of an assay based on the competition between GPCR kinase-2 (GRK2) and G α for G $\beta\gamma$, by measuring BRET between GRK2-GFP10 and RlucII-G γ_5 in the presence or absence of individual overexpressed G α subunits (Fig. 1a)²⁶. Cell treatment with human trypsin (hTrypsin) or SLIGKV-NH₂ induced the activation of members of G_{q/11} (G α_q , G α_{11} , and G α_{15}) and G_{i/o} (G α_{i1} , G α_{i2} , G α_{i3} , G α_{oA} , G α_{oB} , and G α_2) families, as well as G_{12/13}. In contrast, neither G α_s nor G α_{olf} were activated by hPAR2 in response to hTrypsin or SLIGKV-NH₂ (Fig. 1b, c). This promiscuity of PAR2 coupling contrasts with the high selectivity of the M3-muscarinic acetylcholine receptor (M3-mAChR) used as a selectivity control and found to activate only G_{q/11} family members (Supplementary Fig. 1).

The activation of G-protein subtypes was further confirmed using a different BRET²-based assay. Contrary to the GRK-based sensor that was based on the competition between GRK protein and G α subunit to bind G $\beta\gamma$ dimer, this assay directly monitors the separation of G α fused to *Renilla* luciferase (G α -RlucII) from G γ fused to GFP10 (GFP10-G γ) in living cells^{26–28} (Fig. 1d). Both hTrypsin and SLIGKV-NH₂ promoted a rapid and concentration-dependent decrease in BRET² for the human G α_q (Fig. 1e), G α_{i2} (Fig. 1f), G α_{oA} (Fig. 1g), G α_{i2} (Fig. 1h), and G α_{i3} (Fig. 1i) sensors in HEK293 cells co-expressing hPAR2 (Supplementary Fig. 2a). Similar concentration-response curves were observed in HCT 116 cells co-expressing hPAR2 and the human biosensors (Supplementary Fig. 2b). The interspecies correspondence has been validated for G_q and G₁₂ using mouse sequence-based biosensors co-expressed with the mouse receptor (mPAR2) and stimulated by the mouse-selective activating peptide, SLIGRL-NH₂, in mouse rectal carcinoma CMT-93 cells (Supplementary Fig. 2c). A summary of potencies (pEC₅₀) and maximal efficacies (E_{max}) obtained are presented in Supplementary Fig. 2d.

We also compared the responses obtained with the G α and G γ subunits separation biosensors (Fig. 1e–i) to those generated with the GRK-based BRET biosensor (Fig. 1b, c) as X–Y plots (Supplementary Fig. 3). As can be seen in panel a, for each G protein an excellent linear correlation between the two sensors can be seen for all concentrations of hTrypsin. When comparing the maximal response for each G protein using the two sensors, again a straight relationship was observed (Supplementary Fig. 3b). However, the slope of the curve indicates that the two biosensors have slightly different sensitivities for the different G protein; the GRK2-based biosensor shows relatively greater sensitivity for G₁₂ and G_{oA}, whereas the G α and G γ subunits separation sensor shows a greater sensitivity for G_q and G₁₃. It should be noted that, as each biosensor comprised different components, the absolute BRET values do not allow to compare the “coupling strength” among G-protein subtypes but rather allow to determine whether a pathway is activated or not, and





Fig. 1 G-protein activation profile of hPAR2 in response to hTrypsin and SLIGKV-NH₂ in HEK293 cells. **a** Schematic representation of the GRK-based BRET biosensor monitoring the activation of selective G α subunits. Upon agonist stimulation, the G α subunit dissociates from the $\beta\gamma$ dimer (RlucII-G γ_5), allowing GRK2 sensor (GRK2-GFP10) recruitment to the $\beta\gamma$ dimer and leading to an increase in BRET² signal. **b, c** G-protein activation profiles induced by hTrypsin (10 U/mL, 15 min; **b**) or SLIGKV-NH₂ (1 mM, 15 min; **c**) in HEK293 cells expressing hPAR2, and components of the G-protein activation sensor (RlucII-G γ_5 , GRK2-GFP10, G β_1 , and the indicated G α subunit). Results are expressed as BRET² ratio in % of maximal response obtained in mock condition (mean \pm SEM; $n = 4-6$; one-way ANOVA followed by Dunnett's post hoc: * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to mock condition). **d** Schematic representation of the BRET²-based biosensor monitoring the agonist-promoted G α and G γ subunit separation. Upon agonist stimulation, the G α subunit (G α -RlucII) dissociates from the $\beta\gamma$ dimer (GFP10-G γ), leading to a decrease in BRET² signal. **e-i** Dose-response curves of G-protein activation induced by increasing concentrations of hTrypsin or SLIGKV-NH₂ (1 min) in HEK293 cells expressing hPAR2, G β_1 , and the BRET²-based $\alpha/\beta\gamma$ dissociation biosensors (GFP10-G γ_1 (**e, f, h, i**) or GFP10-G γ_2 (**g**) along with the indicated G α -RlucII subunit). Results are expressed as BRET² ratio of absolute values (mean \pm SEM; $n = 3$).

whether and how each of the responses can be modulated by different compounds.

G-protein-dependent signaling pathways activated by PAR2. To further characterize the signaling profile of hPAR2, we evaluated its ability to activate downstream effectors of G proteins.

We first evaluated the coupling of hPAR2 to signaling pathways downstream of G_q protein. In agreement with the results observed for G_q activation, both agonists promoted the production of diacylglycerol (DAG; Fig. 2c and Supplementary Fig. 4a, left panel) and protein kinase C (PKC; Fig. 2d and Supplementary Fig. 4a, central panel) activation as assessed by unimolecular



BRET²-based biosensors (Fig. 2a, b)²⁹. Ca²⁺ mobilization was also stimulated, as detected by the FLIPR-5 fluorescent dye, upon activation of the receptor (Fig. 2e and Supplementary Fig. 4a, right panel). Ca²⁺ release induced by hTrypsin or SLIGKV-NH₂ was completely blocked by pretreatment with the specific G_{q/11} inhibitor YM-254890³⁰, but not by the G_{i/o}-specific inhibitor pertussis toxin (PTX) (Supplementary Fig. 4b, left panel), indicating that intracellular Ca²⁺ release is mediated through the coupling of hPAR2 to G_{q/11} but not G_{i/o}. We also evaluated the role of G_{12/13} in the Ca²⁺ response using HEK293 cells genetically deleted for G₁₂ and G₁₃ proteins by the CRISPR/Cas9 system ($\Delta G_{12/13}$)^{29,31}. G_{12/13} deletion, as well as reintroduction of either

G₁₂ ($\Delta G_{12/13}$: +G₁₂) or G₁₃ ($\Delta G_{12/13}$: +G₁₃) into the KO background, had no impact on the Ca²⁺ response (Supplementary Fig. 4b, right panel), demonstrating that G_{12/13} were not required for hPAR2-mediated Ca²⁺ mobilization. Similar productions of DAG and Ca²⁺, as well as PKC activation were observed following hPAR2 activation in HCT 116 cells and mPAR2 activation by SLIGRL-NH₂ in CMT-93 cells (Supplementary Fig. 4c, d, respectively). A summary of potencies (pEC₅₀) and maximal efficacy (E_{max}) values obtained are presented in Supplementary Fig. 4e.

To evaluate the regulation of adenylate cyclase by hPAR2-activated G_{i/o}, we measured the inhibition of forskolin-induced

Fig. 2 hPAR2 promotes signaling pathways downstream of G_{α_q} , $G_{\alpha_i/or}$ and $G_{\alpha_{12/13}}$ proteins, and β arrestin2 recruitment at the plasma membrane in HEK293 cells. **a** Schematic representation of the unimolecular DAG BRET sensor, which measures the generation of DAG by activated PLC. The recruitment of c1b DAG-binding domain of PKC δ to the plasma membrane by DAG brings RlucII and GFP10 in close proximity, leading to an increase of BRET signal. **b** Schematic representation of the unimolecular PKC BRET sensor. The phosphorylation of PKC consensus sequences (pPKC1 and 2) induces their interaction with phosphothreonine-binding domains (FHA1 and FHA2) of Rad53 and allows a conformational change, leading to the close proximity of RlucII and GFP10 and an increased BRET signal. **c, d** Dose-response curves of DAG production (**c**) and PKC activation (**d**) induced by increasing concentrations of hTrypsin or SLIGKV-NH₂ during 1 (DAG) or 5 min (PKC) in HEK293 cells expressing hPAR2 and the corresponding unimolecular BRET²-based biosensors. Results are expressed as BRET² ratio of absolute values (mean \pm SEM; $n = 3$). **e** Dose-response curves of Ca²⁺ mobilization (increases of peak values in relative fluorescence unit, RFU) induced by increasing concentrations of hTrypsin or SLIGKV-NH₂ in HEK293 cells endogenously expressing hPAR2 (mean \pm SEM; $n = 5-7$). **f** Schematic representation of the unimolecular EPAC BRET sensor, which measures the generation of cAMP by activated adenylate cyclase. cAMP binding to EPAC1 domain induces a conformational change, increasing the distance between RlucII and GFP10, and yielding to a reduction of the BRET signal. **g** Dose-response curves of hPAR2-mediated inhibition of forskolin-induced cAMP production in HEK293 cells expressing hPAR2. Cells expressing EPAC biosensor were stimulated during 5 min with increasing concentrations of SLIGKV-NH₂ and then treated with forskolin (1.5 μ M, 5 min) before measurement of cAMP production. Results are expressed as BRET² ratio of absolute values (mean \pm SEM; $n = 3$). **h** hPAR2-mediated activation of SRF-RE reporter gene, reflecting RhoA activation, induced by hTrypsin (10 U/mL, 6 h) or SLIGKV-NH₂ (100 μ M, 6 h) in HEK293 cells expressing hPAR2. Results are expressed as a ratio of Firefly over *Renilla* luminescence (mean \pm SEM; $n = 3$; one-way ANOVA: ** $p < 0.01$ and *** $p < 0.001$ compared to control cells). **i** ERK1/2 phosphorylation in HEK293 cells expressing hPAR2 and stimulated with hTrypsin (1 U/mL) or SLIGKV-NH₂ (100 μ M) for 10 min. Representative immunoblots of ERK1/2 phosphorylation are shown. Western blottings were quantified and expressed as the ratio of phosphorylated ERK (P-ERK1/2) protein level normalized over total ERK (t-ERK1/2) protein (mean \pm SEM; $n = 4$; one-way ANOVA: *** $p < 0.001$ compared to control cells). **j** Schematic representation of the ebBRET-based assay that monitors energy transfer between β arrestin2-RlucII and rGFP-CAAX targeted to the plasma membrane. **k** Dose-response curves of β arrestin2 recruitment induced by increasing concentrations of hTrypsin or SLIGKV-NH₂ (15 min) in HEK293 cells expressing hPAR2 and ebBRET sensors β arrestin2-RlucII/rGFP-CAAX. Results are expressed as BRET² ratio of absolute values (mean \pm SEM; $n = 3-4$).

cAMP production using the EPAC BRET²-based biosensor (Fig. 2f)³². The forskolin-promoted increase in cAMP level was concentration-dependently blocked by hPAR2 stimulation with SLIGKV-NH₂ (Fig. 2g), illustrated by the increase of BRET² signal compared to forskolin treated cells.

We then evaluated the G_{12/13} protein-dependent activation of RhoA by measuring the induction of serum response factor response element (SRF-RE) reporter gene³³. Treatment of HEK293 cells with both PAR2 agonists induced SRF-RE gene (Fig. 2h), mainly through the G_{12/13} proteins since it was not inhibited by the G_{q/11} inhibitor YM-254890 in wild-type cells (Supplementary Fig. 5a). However, in cells lacking G_{12/13}, the response became G_q-dependent, as addition of YM-254890 in these cells blocked the response (Supplementary Fig. 5b). Reintroduction of either G_{α₁₂} or G_{α₁₃} into the G_{12/13} KO cells potentiated the hTrypsin and SLIGKV-NH₂-promoted responses, while abolishing the YM-254890 effect (Supplementary Fig. 5b). This indicates that, in the absence of G_{12/13}, the G_q coupling can support the SRF-RE activation but that its involvement is minimal when G_{12/13} are present.

Finally, we showed that hPAR2 activation leads to ERK1/2 phosphorylation by both agonists (Fig. 2i) through the activation of G_{β/γ} and G_q/PKC, as it was partially blocked by both the PTX and YM-254890 or the PKC inhibitor Gö 6983 (Supplementary Fig. 6a, b). In contrast, RhoA activation did not contribute to PAR2-mediated activation of ERK1/2, as the specific RhoA inhibitor, CT04, did not affect ERK phosphorylation (Supplementary Fig. 6c). Similarly, β -arrestin engagement was not essential for this activation, as it was also observed in HEK293 cells genetically deleted from β arrestin1/2 by the CRISPR/Cas9 system ($\Delta\beta$ arrestin1/2; Supplementary Fig. 6d).

β arrestin2 recruitment induced by PAR2 activation. We characterized the recruitment of β arrestin2 at the plasma membrane upon hPAR2 stimulation using enhanced bystander BRET (ebBRET) monitoring energy transfer between β arrestin2-RlucII and the plasma membrane-targeted rGFP-CAAX (Fig. 2j)³⁴. Both hTrypsin and SLIGKV-NH₂ induced concentration-dependent recruitment of β arrestin2 at the plasma membrane by hPAR2 in HEK293 cells (Fig. 2k and Supplementary Fig. 7a) and in HCT

116 cells, or by mPAR2 in CMT-93 in response to SLIGRL-NH₂ (Supplementary Fig. 7b, c, respectively). A summary of potencies (pEC₅₀) and maximal efficacies (E_{max}) obtained are presented in Supplementary Fig. 7d.

Interestingly, as recently reported³⁵, the synthetic peptide was found to be more efficacious than hTrypsin to promote the recruitment of β -arrestin. Similar observations were made for G_q and G₁₂ but not for G_{oA} or G₁₂/G₁₃ (Fig. 1e-i and Supplementary Fig. 2). It is unlikely that such difference results from an action on a different GPCR, because, as seen in Supplementary Fig. 7e, no β arrestin2 recruitment could be observed in either parental or KO cells lacking hPAR2 for either SLIGKV-NH₂ or hTrypsin. The recruitment of β arrestin2 required the heterologous expression of hPAR2 in both cases. The most likely hypothesis is that SLIGKV-NH₂ displays functional selectivity compared to hTrypsin favoring β -arrestin, G_q and G₁₂ over G_{12/13}. Mechanistically, this would mean that the synthetic peptide would stabilize a conformation that is somewhat different from the one promoted by the TL, and that the former would be more favorable to β arrestin, G_q and G₁₂ engagement.

Characterization of I-287 as a new PAR2 inhibitor. I-287 (Fig. 3a) was discovered by Vertex Pharmaceuticals as a potent inhibitor of PAR2, as part of a drug discovery research program aimed at identifying novel therapeutics²². To further characterize the properties of this compound, Schild analyses of the effects of I-287 on the trypsin- and SLIGKV-Ca²⁺ responses and on the activation of G_q and G₁₂ (through $\beta\gamma$), which are known to promote Ca²⁺ mobilization, were conducted. Concentration-dependent rightward shifts of the Ca²⁺ response (Fig. 3b) and G_q activation (Fig. 3c) stimulated by either agonist were observed. No such inhibitory action of I-287 was observed for PAR2-mediated G₁₂ activation (Fig. 3d). The G-protein subtype-selective inhibition observed for I-287 suggest an allosteric mode of action, as a competitive inhibitor would be expected to block the activation of both G-protein subtypes engaged by the receptor. Consistent with such an allosteric mode of action is the observation of both the rightward shifts collapse at the highest concentrations of the antagonist and the insurmountable aspect of the inhibition. This non-competitive mode of action strongly suggests that I-287 is a




Fig. 3 Identification of I-287 as a negative PAR2 allosteric modulator.

a Chemical structure of compound I-287. **b** Impact of I-287 pretreatment (30 min) on the Ca^{2+} responses evoked by increasing concentrations of hTrypsin (left panel) or SLIGKV-NH₂ (right panel) in HEK293 cells endogenously expressing hPAR2. Results are expressed as % of the maximal induced-response in the absence of I-287 (% activity; mean \pm SEM; $n = 3-6$). **c, d** Impact of I-287 pretreatment (15 min) on the G_{α_q} (c) and $\text{G}_{\alpha_{12}}$ (d) proteins activation induced after 1 min stimulation with increasing concentrations of hTrypsin (left panel) or SLIGKV-NH₂ (right panel) in HEK293 cells co-expressing hPAR2 and the human BRET²-based biosensors G_{α_q} -RlucII or $\text{G}_{\alpha_{12}}$ -RlucII and GFP10-G γ_1 . Results are expressed as BRET² ratio of absolute values (mean \pm SEM; $n = 3$).

negative allosteric modulator (NAM) and not an orthosteric competitive antagonist of hPAR2.

I-287 inhibits PAR2-mediated activation of G_q and $\text{G}_{12/13}$ but not $\text{G}_{i/o}$ proteins. Given the functional selectivity of I-287 toward G_q vs. G_i , we further investigated the effect of this NAM on the activation of G_{α_q} , $\text{G}_{\alpha_{12}}$, $\text{G}_{\alpha_{13}}$, $\text{G}_{\alpha_{12/13}}$, and $\text{G}_{\alpha_{13}}$ using the BRET²-based assays described previously. The concentration-dependent inhibition was tested using an EC₈₀ concentration of agonist in HEK293 cells. The results, expressed as a % of the response induced by the agonists alone, show that I-287 inhibited both G_q and G_{13} (Fig. 4a, e) activation induced by either hTrypsin or SLIGKV-NH₂ with IC₅₀s between 45 and 390 nM (see Supplementary Fig. 8d), but was without effect on the activation of G_{12}

and G_{α_A} (Fig. 4b, c). A similar G-protein subtype-selective effect of I-287 was observed in HCT 116 cells expressing hPAR2 (Supplementary Fig. 8a, d), and mPAR2 signaling in CMT-93 cells (Supplementary Fig. 8c, d), thus illustrating the inter-cell lines and the interspecies preservation of I-287 pathway-selective inhibitory effect on PAR2 signaling.

In contrast to the clear inhibition observed for G_{13} (Fig. 4e), for G_{12} , the effect of I-287 observed in both HEK293 and HCT 116 cell lines was ambiguous (Fig. 4d and Supplementary Fig. 8a). To further characterize the engagement of $\text{G}_{12/13}$ by PAR2 and its inhibition by I-287, we used a new ebBRET-based assay that monitors the recruitment of the selective $\text{G}_{12/13}$ effector, p115-RhoGEF, to the activated (GTP-bound) G proteins (Fig. 4f). hTrypsin promoted an increase in ebBRET signal between p115-RhoGEF-RlucII and rGFP-CAAX (Fig. 4g), which was not affected neither by YM-254890, nor PTX (Supplementary Fig. 9a, left and central panel). In addition, hTrypsin promoted an ebBRET increase in HEK293 cells genetically deleted for $\text{G}_{\alpha_{12}}$ and $\text{G}_{\alpha_{13}}$ proteins ($\Delta\text{G}_{12/13}$)^{29,31} only following reintroduction of either $\text{G}_{\alpha_{12}}$ ($\Delta\text{G}_{12/13}$: + G_{12}) or $\text{G}_{\alpha_{13}}$ ($\Delta\text{G}_{12/13}$: + G_{13}) (Supplementary Fig. 9a, right panel). Similar results were observed with the activation of the human thromboxane A₂ receptor (hTPaR), a well-documented $\text{G}_{12/13}$ activating receptor, by U46691 (Supplementary Fig. 9b), validating the selectivity of the sensor for the activation of the $\text{G}_{12/13}$ protein family members. Using this p115-RhoGEF-RlucII/rGFP-CAAX biosensors, we confirmed that I-287 can inhibit the responses evoked by both G_{12} and G_{13} (Fig. 4h). Finally, the selectivity of I-287 toward PAR2 is illustrated by the fact that it did not affect the activation of G_{α_q} induced by carbachol stimulation of M3-mAChR or $\text{G}_{\alpha_{12}}$ and $\text{G}_{\alpha_{13}}$ induced by U46691 stimulation of hTPaR (Supplementary Fig. 8b).

I-287 inhibits PAR2-mediated activation of DAG/ Ca^{2+} /PKC, RhoA, SRF-RE, and FAK signaling pathways.

We then examined the impact of I-287 on hPAR2-mediated activation of signaling pathways downstream of G_{α_q} and $\text{G}_{\alpha_{12/13}}$ by monitoring DAG/ Ca^{2+} /PKC and RhoA/FAK/SRF-RE pathways in HEK293 cells. Consistent with the ability of I-287 to inhibit G_q , the NAM also blocked DAG production (Fig. 5a), PKC activation (Fig. 5b), as well as Ca^{2+} mobilization (Fig. 5c) with IC₅₀s ranging from 10 to 500 nM depending of the pathway (see Supplementary Fig. 10e). A similar profile was observed in hPAR2-expressing HCT 116 and mPAR2-expressing CMT-93 cells, respectively (Supplementary Fig. 10a, b, e). In contrast, I-287 had no significant impact on DAG or PKC signaling pathways induced by carbachol stimulation of M3-mAChR (Supplementary Fig. 10c), confirming its selectivity for PAR2. However, an inhibitory action on the Ca^{2+} and PKC responses were observed but only at very high concentration (>1 μM) suggesting an off-target effect of the compound at very high concentration for these sensitive assay (Supplementary Fig. 10c). We cannot exclude the possibility of a shared allosteric site common to other G_q coupled receptors. However, no such effect was observed on M3R-mediated G_q activation measured directly (see Supplementary Fig. 8b).

Given that I-287 blocked $\text{G}_{\alpha_{12/13}}$ activation, we evaluated if the compound also affected downstream RhoA signaling by measuring the SRF-RE reporter gene induction in response to hPAR2 activation by hTrypsin or SLIGKV-NH₂. In agreement with the effect observed on $\text{G}_{\alpha_{12/13}}$, pretreatment with I-287 significantly reduced the induction of SRF-RE reporter gene promoted by the two agonists (Fig. 5d). A similar inhibition was observed on SRF-RE gene induction mediated by hPAR2 stimulation by both agonists in HCT 116 cells (Supplementary Fig. 10d). This effect is selective for hPAR2, as I-287 had no effect on SRF-RE induction




Fig. 4 Biased effect of I-287 on hPAR2-promoted Gα protein activation. **a–e** Impact of I-287 on hPAR2-promoted G-protein activation measured by BRET². HEK293 cells co-expressing hPAR2 and the human BRET²-based α/βγ dissociation biosensors (GFP10-Gγ₁ or GFP10-Gγ₂ along with the indicated Gα-RlucII subunit), were pretreated with increasing concentrations of I-287 for 15 min followed by 1 min stimulation with an EC₈₀ concentration of hTrypsin or SLIGKV-NH₂. Results are expressed as ΔBRET in % of the response induced by EC₈₀ of respective agonists in the absence of I-287 (mean ± SEM; n = 3–6). **f** Schematic representation of the ebBRET-based biosensor to selectively monitor Gα_{12/13} activation. Upon agonist stimulation, activated Gα₁₂ or Gα₁₃ subunits recruit their selective effector p115-RhoGEF tagged with RlucII to the plasma membrane, leading to an increase of ebBRET with the membrane-anchored rGFP-CAAX. **g** Dose-response curves of p115-RhoGEF recruitment at the plasma membrane induced by increasing concentrations of hTrypsin for 1 min in HEK293 cells expressing hPAR2 and the p115-RhoGEF-RlucII/rGFP-CAAX sensors in the absence (mock) or in the presence of Gα₁₂ or Gα₁₃ subunits. Results are expressed as BRET² ratio of absolute values (mean ± SEM; n = 4). **h** Inhibitory action of increasing concentrations of I-287 (15 min) on the G_{12/13}-mediated recruitment of p115-RhoGEF at plasma membrane induced by an EC₈₀ concentration of hTrypsin in HEK293 cells co-expressing hPAR2 and the human BRET²-based biosensors p115-RhoGEF-RlucII/rGFP-CAAX along with Gα₁₂ or Gα₁₃ subunits. Results are expressed as ΔBRET in % of the response induced by EC₈₀ of hTrypsin in the absence of I-287 (mean ± SEM; n = 3).

mediated by 10% fetal bovine serum (FBS), a known activator of RhoA/ROCK pathway, in HEK293 (Fig. 5d) and HCT 116 (Supplementary Fig. 10d) cells. Finally, we determined whether the inhibition of Gα_q and Gα_{12/13} could impact the activity of a protein involved in cytoskeletal reorganization, the focal adhesion kinase (FAK), known to be regulated by this axis³⁶. As shown in Fig. 5e, I-287 significantly inhibited the SLIGKV-NH₂-induced FAK phosphorylation after 40 and 60 min of agonist stimulation. Although a similar tendency was observed for the hTrypsin promoted response, the inhibition did not reach statistical significance.

I-287 inhibits PAR2-mediated ERK1/2 activation. We then assessed the impact of I-287 on ligand-promoted activation of ERK1/2 in HEK293 cells expressing hPAR2. Pretreatment of cells with I-287 significantly inhibited the time-dependent activation of ERK1/2 induced by hTrypsin and SLIGKV-NH₂ (Fig. 5f). Given that we showed that PAR2-induced ERK1/2 activation is mediated by G_{q/11} and G_{i/o} proteins (Supplementary Fig. 6), our results strongly suggest that I-287 mediated its action on ERK1/2 through the inhibition of G_q/DAG/ Ca²⁺/PKC cascade.

I-287 has no effect on PAR2-mediated recruitment of βarrestin2 and receptor internalization. We then evaluated the impact

of I-287 on hPAR2-mediated recruitment of βarrestin2 at the plasma membrane. I-287 did not affect the ebBRET signal between βarrestin2-RlucII and rGFP-CAAX promoted by both agonist stimulation of hPAR2 in either HEK293 (Fig. 6a) or HCT 116 cells, nor in mPAR2-expressing CMT-93 cells (Supplementary Fig. 10a, b, respectively).

We next sought to determine whether I-287 could affect the ligand-promoted endocytosis of hPAR2. For this purpose, we monitored ebBRET between *Renilla* luciferase-tagged receptor (hPAR2-RlucII) and the plasma membrane-anchored rGFP-CAAX (Fig. 6b). Both PAR2 agonists induced a reduction in BRET signal reflecting the loss of cell surface receptor resulting from its endocytosis. Pretreatment of cells with I-287 had no significant impact on neither the half-time nor on the maximal internalization induced by both agonists (Fig. 6c).

I-287 inhibits PAR2-mediated IL-8 cytokine release. To determine whether PAR2 inhibition by I-287 may have anti-inflammatory effects, we assessed its ability to block the PAR2-mediated release of the inflammatory cytokine interleukin-8 (IL-8) in HCT 116 and human lung carcinoma (A549) cells. As shown in Fig. 7a, b, I-287 significantly blocked IL-8 secretion promoted by both hTrypsin and SLIGKV-NH₂ in the two cell lines. No such inhibitory action of I-287 was observed on the




Fig. 5 I-287 inhibits PAR2-mediated activation of DAG/Ca²⁺/PKC and RhoA/SRF-RE, as well as FAK and ERK1/2 signaling pathways. **a, b** Impact of increasing concentrations of I-287 (15 min) on DAG production (**a**) and PKC activation (**b**) induced after 1 (DAG) or 5 (PKC) min stimulation with an EC₈₀ concentration of hTrypsin or SLIGKV-NH₂ in HEK293 cells co-expressing hPAR2 and the indicated unimolecular BRET²-based biosensors. Results are expressed as Δ BRET in % of the response induced by EC₈₀ of respective agonists in the absence of I-287 (mean \pm SEM; *n* = 4–5). **c** Impact of increasing concentrations of I-287 (30 min) on intracellular Ca²⁺ mobilization induced by an EC₈₀ concentration of hTrypsin or SLIGKV-NH₂ in HEK293 cells endogenously expressing hPAR2. Results are expressed as % of the response induced by respective agonists in the absence of I-287 (mean \pm SEM; *n* = 3–4). **d** Impact of I-287 (10 μ M, 30 min) on hPAR2-promoted SRF-RE reporter gene activation induced after 6 h stimulation with hTrypsin (10 U/mL) or SLIGKV-NH₂ (100 μ M) in HEK293 cells expressing hPAR2. FBS (10%) was used as control. Results are expressed as % of the response induced by respective agonists in the absence of I-287 (mean \pm SEM; *n* = 3–5; unpaired *t*-test: **p* < 0.05 and ***p* < 0.01 compared to respective control cells, ns: non-significant). **e, f** Kinetics of FAK and ERK1/2 phosphorylation in HEK293 cells expressing hPAR2 and pretreated with DMSO or I-287 (10 μ M, 30 min) before stimulation with hTrypsin (1 U/mL) or SLIGKV-NH₂ (100 μ M) at the indicated times. Representative immunoblots of FAK and ERK1/2 phosphorylation are shown. Western blots were quantified and expressed as the ratio of phosphorylated protein level (P-FAK or P-ERK1/2) normalized over total protein (t-FAK or t-ERK1/2; mean \pm SEM; *n* = 3–5; two-way ANOVA followed by Tukey's post hoc test: **p* < 0.05, ***p* < 0.01, and ****p* < 0.001 compared to DMSO-treated cells at the respective time).

tumor necrosis factor- α (TNF- α)-stimulated IL-8 secretion (Supplementary Fig. 11), supporting the selectivity of action. Surprisingly, I-287 pretreatment potentiated the IL-8 secretion elicited by TNF- α in HCT 116 cells (Supplementary Fig. 11a). This unexpected effect was not observed in A549 cells (Supplementary Fig. 11b), suggesting a cell-type-specific interaction between PAR2 and TNF- α pathways.

I-287 reduces CFA-induced inflammation in mice. The *in vivo* anti-inflammatory properties of I-287 were then evaluated in the complete Freund's adjuvant (CFA)-induced paw edema model in mice. CFA induced a time-dependent increase of the paw volume that was significantly reduced by oral administration (50 mg/kg)

of I-287 3 h following the CFA treatment (Fig. 7c). This inhibitory action of I-287 was comparable to that of Ibuprofen (140 mg/kg), used as positive control. These results demonstrate that the functionally selective PAR2 antagonist I-287 is an orally active compound displaying an anti-inflammatory efficacy equivalent to one of the most used nonsteroidal anti-inflammatory drugs (NSAIDs) in the mice paw edema model. The good bioavailability of this compound measured in rats (58% bioavailability)²², suggests that I-287 is a good tool compound to study the anti-inflammatory actions of PAR2. Despite the fact that potentiating effect of I-287 on the TNF- α -promoted IL-8 secretion appears to be cell specific this potential caveat should be considered in studying its anti-inflammatory effectiveness.




Fig. 6 I-287 has no effect on β arrestin2 recruitment and PAR2 internalization. **a** Impact of increasing concentrations of I-287 (15 min) on β arrestin2 recruitment at the plasma membrane induced by an EC_{80} concentration of hTrypsin or SLIGKV-NH₂ (15 min) in HEK293 cells co-expressing hPAR2 and the ebbRET sensors β arrestin2-RlucII/rGFP-CAAX. Results are expressed as Δ BRET in % of the response induced by EC_{80} of respective agonists in the absence of I-287 (mean \pm SEM; $n = 5$). **b** Schematic representation of receptor internalization BRET-based biosensor using the hPAR2-RlucII and rGFP-CAAX sensors to monitor loss of hPAR2 from cell surface. **c** Impact of I-287 (1 μ M, 15 min) on hPAR2 internalization kinetics induced by an EC_{80} concentration of hTrypsin or SLIGKV-NH₂ in HEK293 cells expressing the hPAR2-RlucII/rGFP-CAAX sensors. Results are expressed as BRET² ratio of absolute values (mean \pm SEM; $n = 3$).




Fig. 7 I-287 inhibits PAR2-induced secretion of IL-8 cytokine in vitro and reduces CFA-induced inflammation in mice. **a, b** Impact of I-287 (10 μ M, 30 min) on hPAR2-promoted IL-8 cytokine release induced after 6 h stimulation with vehicle, hTrypsin (1 U/mL) or SLIGKV-NH₂ (100 μ M) in culture medium of HCT 116 (**a**) and A549 (**b**) cells expressing hPAR2. Data are expressed as IL-8 concentration in pg/mL (mean \pm SEM; $n = 3-5$; two-way ANOVA followed by Tukey's post hoc test: *** $p < 0.001$ compared to control cells with vehicle; ## $p < 0.01$ and ### $p < 0.001$ compared to control cells with respective agonist). **c** Impact of I-287 on complete Freund's adjuvant (CFA)-induced inflammation in mice. One hour after CFA injection, mice were given I-287 (50 mg/kg) or vehicle (95% TPGS - 5% NMP) by gavage. A group of animals received Ibuprofen (140 mg/kg) as a reference drug. The volume of the hindpaw was measured every hour to evaluate swelling/inflammation using a plethysmometer (mean \pm SEM; $n = 6$ for vehicle and I-287 groups and $n = 8$ for Ibuprofen group; two-way repeated-measures ANOVA followed by Dunnett's post hoc test: * $p < 0.05$ for I-287 vs. vehicle and ## $p < 0.01$, ### $p < 0.001$ for Ibuprofen vs. vehicle).

Discussion

Although PAR2 has been implicated in the pathogenesis of several IMIDs and cancers^{2,37,38}, only a limited number of

compounds able to block its action are currently available. The present study characterized I-287, a new PAR2-selective NAM that displays functional selectivity by inhibiting trypsin- and SLIGKV-NH₂-mediated activation of G_q and G_{12/13} and their downstream signaling pathways without affecting G_{i/o} activation, nor affecting β arrestin2 recruitment and the resulting PAR2 internalization. Given the inhibitory action of I-287 on IL-8 secretion and on CFA-induced inflammatory response, the data demonstrate that blocking the G_q and G_{12/13} pathways is sufficient to promote PAR2-mediated anti-inflammatory effects.

It is now recognized that GPCR-targeting ligands can differentially modulate the activity of the various signaling pathways engaged by a single receptor with potential therapeutic advantage³⁹. To capitalize on this phenomenon, known as functional selectivity or ligand-biased signaling, it is necessary to determine which pathways are essential for the therapeutic activity. In the present study, we used BRET²- and ebbRET-based biosensors to characterize the signaling repertoire for the anti-inflammatory action of PAR2 blockade. The direct monitoring of G-protein activation confirmed the coupling promiscuity of PAR2^{1,2,23-25,40} engaging all G-protein sub-families, except for G_s, in response to hTrypsin and SLIGKV-NH₂. Previous works has suggested that the G_s/cAMP production pathway could also be activated by PAR2^{6,40,41}. We also found a weak cAMP production in response to trypsin but not SLIGKV-NH₂ and the response to trypsin was also observed in PAR2 KO cells (Supplementary Fig. 12), indicating that the response may not be PAR2 specific.

Our data clearly reveal that I-287 acts as a biased NAM. Although a number of biased orthosteric ligands have now been described, I-287 adds to a short list of biased allosteric ligands (e.g., see refs. 42-44). It should also be noted that while most examples of biased ligands describe selectivity between G-protein activation and β -arrestins recruitment, I-287 not only displays bias between G proteins and β -arrestin but also among different G-protein subtypes, acting as a NAM for G_q and G_{12/13} but not G_{i/o}. To date, only a limited number of antagonists targeting PAR2 have been described^{45,46}. Among them, only one has been described as a biased antagonist until now. Indeed, GB88 selectively inhibits Ca²⁺ and PKC signaling whereas acting as a PAR2-agonist for the G_{i/o} pathway by reducing forskolin-stimulated cAMP, and in promoting ERK1/2 phosphorylation, RhoA activation, and β arrestin2 recruitment^{7,9,47,48}. In contrast to GB88, I-287 displays no intrinsic agonist or inverse agonist activity towards any of the pathways tested (data not shown).

Another PAR2 antagonist, I-191, was reported to be an antagonist blocking all the pathways tested, including Ca^{2+} release, ERK1/2 phosphorylation, RhoA activation, and inhibition of forskolin-induced cAMP accumulation⁴⁹. Finally, four other compounds, the P2pal-18S i3 loop pepducin, the I-343, and AstraZeneca's compounds AZ8838 and AZ3451, have been tested only for a limited subset of signaling pathways and found to be antagonists for all those tested^{41,46,50}.

To our knowledge, our study is the first to report the ability of a PAR2 ligand to potently inhibit $G_{12/13}$ activation. A previous study had reported the inhibition of PAR2-mediated RhoA activation by I-191⁴⁹ but, given that both $G_{12/13}$ and G_q can activate RhoA^{51,52}, whether this inhibition was G_q - or $G_{12/13}$ -mediated was unknown. Our study indicates that, in fact, both pathways can contribute. This is illustrated by the ability of the G_q inhibitor, YM-254890, to block PAR2-promoted SRF-RE induction only in $G_{12/13}$ KO cells. Such complementary action of $G_{12/13}$ and G_q in the activation of the RhoA pathways has previously been reported for the angiotensin receptor²⁹. The inhibitory action of I-287 on G_q and $G_{12/13}$ was further confirmed by its action on DAG and Ca^{2+} production, PKC and SRF-RE activation, as well as ERK and FAK phosphorylation.

Recently, several studies have reported different structures of the PAR2 receptor in complex with ligands, using crystallography or computational modeling studies^{46,53,54}. Among them, the binding sites of two different NAMs (AZ8838 and AZ3451) were reported. Whereas AZ8838 binds in a pocket lined by residues from TM1–3, TM7, and ECL2, AZ3451 acts as a NAM by occupying a site formed by TM helices 2, 3, and 4, and faces the lipid bilayer⁴⁶. Given the structure of I-287, it is unlikely that it could occupy these newly described binding pocket. For instance, attempts to overlay I-287 with AZ8838 and AZ3451 show no similarity between the molecules. More importantly, they do not share critical structural pharmacophore features that could support a common structure–activity relationships (SAR). Moreover, AZ8838 is completely buried in a small binding pocket that would be too small to accommodate I-287. Also, the SAR of I-287²² illustrates that large substituents can be appended to the piperazine portion of the molecule with no impact on potency, inconsistent with the enclosed small pocket for AZ8838. Concerning AZ3451, the planar shape of I-287 and its biophysical properties (namely its carboxylic acid) makes it unlikely that it could bind in the described highly lipophilic pocket. The identification of I-287 binding remains to be determined and will require additional studies.

One of the salient finding of our study is the fact that inhibition of G_q and $G_{12/13}$ without affecting $G_{i/o}$ activation or β arrestin recruitment is sufficient for the anti-inflammatory action of I-287. This is consistent with previous studies showing that IL-8 secretion in airway epithelial cells is regulated by PAR2-mediated activation of PLC β / Ca^{2+} pathway⁵⁵, and that neutrophil adhesion to lung A549 cancer cells is enhanced via the reorganization of actin and cytoskeleton through Rho/ROCK- and FAK-dependent pathways upon PAR2 stimulation⁵⁶. Our study is the first to evaluate the impact of PAR2 antagonist on β arrestin recruitment and receptor internalization. Our results reveal that I-287 have no impact on these processes. PAR2-recruitment of β arrestin has been shown to contribute to immune and cancer cells migration as scaffolding protein^{57,58} or to the mediation of pro-inflammatory effects in the airway⁵⁹ and, thus, blocking β arrestin could present some advantages. However, given that blocking β arrestin and the resulting endocytosis would favor the maintenance of active receptor at the plasma membrane which could promote inflammatory response, a compound such as I-287 that does not favor or inhibit the recruitment of β arrestin could also represent an advantage. Consistent with the notion that blocking G_q and $G_{12/13}$ but not β arrestin could be beneficial is the

proposed role of β -arrestin recruitment by PAR2 in wound healing, notably through the activation of ERK1/2 pathway^{60,61}. Whether the functional selectivity towards the G_q and $G_{12/13}$ vs. $G_{i/o}$ would represent a therapeutic advantage remains to be investigated. Indeed, although PAR2-mediated activation of $G_{i/o}$ has been involved in breast cancer cell chemokinesis⁶² and lung adenocarcinoma cell lines migration⁶³, this pathway has also been involved in expression induction of cyclooxygenase-2^{64,65}, which displays protective functions in the gastrointestinal tract⁶⁶.

In conclusion, our study characterized I-287 as a new potent and functionally selective NAM for PAR2 that displays anti-inflammatory properties in vitro and in vivo. It also identified a subset of pathways which blockade is sufficient to promote PAR2-mediated anti-inflammatory effects (Fig. 8). The pathway-specific action of I-287 demonstrates that the development of functionally selective allosteric modulators with the desired physiological outcome is possible. This opens the path for the development of drugs selectively targeting only the therapeutically relevant pathways, thus reducing the liabilities associated with the blocking of the other pathways. Given that recent epidemiologic studies estimates that 5–7% of the population in western societies will be affected by one of IMIDs conditions and that a steady increase in this incidence is predicted^{67,68}, the identification and the development of potent and selective inhibitors of PAR2 signaling pathways such as I-287 could therefore represent a promising therapeutics for the treatment of inflammation and nociception caused by inflammation, cancer, or injury.

Methods

Reagents. hTrypsin was from Sigma-Aldrich, SLIGKV-NH₂ peptide was from Tocris, and SLIGRL-NH₂ peptide from Abcam. Experimental protocols describing the synthesis of I-287 compound is provided in the Supplementary Methods.

Plasmids. hPAR2 cDNA plasmid was purchased from Origen (IBD90.1 clone; catalog number SC322345), where the serine in position 291 has been mutated in threonine (S291T) to reproduce the hPAR2 phenotype observed in HEK293 and HCT 116 cells. For hPAR2-RlucII, we cloned hPAR2 sequence between the NheI and BamHI sites of pCDNA3.1/Zeo(+)-RlucII vector. Mouse PAR2 (mPAR2) cDNA plasmid was purchased from R&D Systems (catalog number RDC0167) and cloned between the BamHI and XbaI sites of pCDNA3.1/Zeo(+)-vector. Human 3xHA-M3-mAChR has been purchased from UMR cDNA Resource Center (catalog number MAR030TN00). Plasmids encoding all the different non-tagged




Fig. 8 Effect of I-287 on intracellular signaling pathways induced by the two human PAR2 agonists, Trypsin, and SLIGKV-NH₂. The pathways inhibited by I-287 are in black, whereas the unaffected pathways are in gray.

human G proteins used in this study were purchased from the Missouri University of Science and Technology (www.cdn.org). Non-tagged mouse G proteins were either PCR-amplified using a Riken mouse cDNA book⁶⁹ or synthesized (GeneART, ThermoFisher). All the G proteins were subcloned into pCDNA3.1(+) vector. mG α_q -RlucII were constructed by PCR-amplifying RlucII coding sequence and inserting it into pCDNA3.1(+) plasmid expressing the mG α_q using Gibson assembly. mG γ_1 -GFP10 was generated by subcloning the GFP10-tag sequence into pCDNA3.1-mG γ_1 . The constructs encoding the G $_{12/13}$ binding domain of the human p115-RhoGEF (residues 1–244) tagged with RlucII were done by PCR amplification from IMAGE clones (OpenBiosystems) and subcloned by Gibson assembly in pCDNA3.1 Hygro(+) GFP10-RlucII, replacing GFP10. A peptidic linker (RLKLPAT) is present between RlucII and the G $_{12/13}$ binding domain. The following plasmids were previously described: human G-protein subunits, GRK2-GFP10, and G γ_5 -RlucII biosensors²⁶; G α_q -118-RlucII, G α_{12} -91-RlucII, G α_{oA} -99-RlucII, G α_{12} -136-RlucII, G α_{13} -130-RlucII, and GFP10-G γ_1 or -G γ_2 ^{26–28}; mG α_{12} -RlucII and mG γ_2 -GFP10 mouse biosensors⁷⁰; unimolecular BRET²-based DAG, PKC, and EPAC biosensors^{29,32}, and rGFP-CAAX with human or mouse β arrestin2-RlucII^{34,70} and HA-TPA⁷¹.

Cell culture. All cell culture reagents were from Wisent, Inc. HEK293, mouse rectal carcinoma (CMT-93), human colon carcinoma (HCT 116), and human lung carcinoma (A549) cells were obtained from the American Type Culture Collection. All cell lines were cultured in complete medium containing Dulbecco's modified Eagle's medium supplemented with 10% FBS and 1% antibiotics (100 U/mL penicillin and 100 μ g/mL streptomycin; PS), except for HCT 116 cell line, which was grown in McCoy's 5a Medium Modified supplemented with 10% FBS and 1% PS. Cells were passaged weekly and incubated at 37 °C in a humidified atmosphere with 5% CO₂. HEK293 cells devoid of functional G α_{12} and G α_{13} proteins (Δ G $_{12}$ /G $_{13}$), a gift from A. Inoue (Tohoku University, Sendai, Miyagi, Japan), were previously described^{29,31}. HEK293 cells devoid of functional β arrestin1/2 by the CRISPR/Cas9 system (Δ β arrestin1/2), a gift from S. Laporte (McGill University, Montreal, Quebec, Canada), were previously described⁷². HEK293 cells devoid of functional hPAR2 have been generated by the CRISPR/Cas9 system.

Bioluminescence resonance energy transfer measurement. Forty-eight hours before the experiments, 1 μ g of total DNA (adjusted with salmon sperm DNA; Invitrogen) was used to transfect 3.5×10^5 cells per mL using linear poly-ethylenimine (PEI, 1 mg/mL; Polysciences) diluted in NaCl (150 mM pH 7.0) as a transfecting agent (3 : 1 PEI/DNA ratio). Cells were immediately seeded (3.5×10^4 cells/well) in poly-ornithine- (Sigma-Aldrich) coated 96-well white microplates (PerkinElmer). Cells were maintained in culture for the next 48 h and BRET experiments carried out.

G-protein activation profile was elucidated with the GRK-based BRET² biosensor, based on the competition between G α subunit and GRK2 protein to bind the β dimer, by transfecting cells with hPAR2 and human G β_1 , RlucII-G γ_5 , and GRK2-GFP10 along with the indicated human G α subunit. hPAR2-mediated activation of G α proteins was confirmed employing human BRET² biosensors based on the separation of human G α -RlucII and GFP10-G γ in the presence of G β_1 ^{26–28}. For mPAR2, cells were co-transfected with the mouse biosensors mG α_q -RlucII/mG γ_1 -GFP10 or mG α_{12} -RlucII/mG γ_2 -GFP10⁷⁰. DAG production and PKC activation were evaluated in cells transiently expressing hPAR2 or mPAR2 and unimolecular BRET²-based DAG or PKC biosensors²⁹. β -Arrestin recruitment to the plasma membrane was determined using β arrestin2-RlucII and a plasma membrane marker for the use in ebBRET assays, composed of the *Renilla reniformis* GFP (rGFP) fused at the C terminus to a plasma membrane-targeting domain composed of the polybasic sequence and prenylation CAAX box of KRAS (rGFP-CAAX)³⁴. PAR2 internalization was evaluated by measuring the disappearance of hPAR2-RlucII from the plasma membrane labeled with rGFP-CAAX. The effector membrane translocation BRET biosensors p115-RhoGEF-RlucII has been used to monitor activation of G $\alpha_{12/13}$ proteins by following the recruitment of this selective effector of activated G $\alpha_{12/13}$ subunits to the plasma membrane tagged with the anchored rGFP-CAAX. A summary of BRET-based biosensors used in the study is presented in Supplementary Table 1.

The day of the experiment, cells were washed with phosphate-buffered saline (PBS) and incubated in Tyrode Hepes buffer (137 mM NaCl, 0.9 mM KCl, 1 mM MgCl₂, 11.9 mM NaHCO₃, 3.6 mM NaH₂PO₄, 25 mM HEPES, 5.5 mM D-Glucose, and 1 mM CaCl₂ pH 7.4) for 1 h at 37 °C. Cells were then treated with increasing concentrations of ligands for the indicated times at 37 °C. The luciferase substrates Coelenterazine 400a (2.5 μ M, NanoLight Technologies) or Prolume purple for internalization experiments (2 μ M, NanoLight Technologies) were added to the wells 5 min before measurements. Plates were read on the TriStar² LB 942 Multimode Microplate Reader (Berthold Technologies) with the energy donor filter (410 \pm 80 nm; RlucII) and energy acceptor filter (515 \pm 40 nm; GFP10 and rGFP-CAAX). BRET signal (BRET²) was determined by calculating the ratio of the light intensity emitted by the acceptor (515 nm) over the light intensity emitted by the donor (410 nm). The agonist-promoted BRET signal (Δ BRET) refers to the difference in BRET recorded from cells treated with agonist and cells treated with vehicle. For the agonist dose–response curves, the percentage of the response of the indicated condition (% E_{max} of agonist or transfection condition) was calculated from the Δ BRET value obtained from a given condition divided by the Δ BRET obtained from the control

condition (e.g., hTrypsin for hPAR2, SLIGRL-NH₂ for mPAR2, or control cells) and multiplied by 100. Data are expressed as mean of at least three independent experiments \pm SEM.

To evaluate the impact of compound I-287 on PAR2 signaling, cells were preincubated for 15–30 min with dimethyl sulfoxide (DMSO) or I-287 at the indicated concentrations, always keeping DMSO at 1% final concentration in each well. Cells were then treated with vehicle or an EC₈₀ concentration of the indicated agonist, determined from the dose–response curves obtained in PAR2 signaling characterization, and BRET signal was recorded as described above.

Ca²⁺ measurement. Forty-eight hours after seeding (3.5×10^4 cells/well) in poly-ornithine-coated, 96-well clear-bottom black microplates (Perkin Elmer), cells were incubated with 100 μ L of a Ca²⁺-sensitive dye-loading buffer (FLIPR calcium 5 assay kit, Molecular Devices) containing 2.5 mM probenecid for 1 h at 37 °C in a 5% CO₂ incubator. During a data run, cells in individual wells were exposed to various concentrations of drugs and fluorescent signals were recorded every 1.5 s for 3 min using the FlexStation II microplate reader (Molecular Devices). Increases in intracellular Ca²⁺ levels were determined by subtracting basal values from peak values. To assess the role of G proteins in PAR2-mediated Ca²⁺ release, cells were pretreated either with PTX (100 ng/mL, 18 h; List Biological Laboratories) or YM-254890 (1 μ M, 30 min; Wako Pure Chemical Industries) before agonist stimulation.

cAMP assay. Cells were transiently transfected with hPAR2 and EPAC BRET²-based biosensor using PEI and immediately seeded (3.5×10^4 cells/well) in poly-ornithine-coated, 96-well white microplates. Forty-eight hours later, cells were washed with PBS and incubated in Tyrode Hepes buffer for 1 h at 37 °C. To measure cAMP modulation in response to G $\beta\gamma$ -activation, cells were first treated for 5 min with increasing concentrations of SLIGKV-NH₂ and then stimulated with forskolin (1.5 μ M, 5 min) in the presence of Coelenterazine 400a (2.5 μ L) and BRET signal was recorded as described above.

SRF-RE reporter gene assay. Cells were transiently transfected with hPAR2 and the pGL4.34[luc2P/SRF-RE/Hygro] vector (Promega) that contains a SRF-RE driving the transcription of a firefly luciferase reporter gene (luc2P) upon SRF activation. The pCDNA3.1(+)-RlucII plasmid expressing *Renilla* luciferase reporter gene was systematically used as an internal control to normalize for transfection efficiency. Cells were immediately seeded (3.5×10^4 cells/well) after transfection in 96-well white microplates (Perkin Elmer). Five hours after, medium was changed for respective culture medium supplemented with 0.5% FBS and cells were incubated for 16 h at 37 °C. Impact of compound I-287 on PAR2-induced SRF-RE activation was tested by preincubating cells for 30 min with DMSO or I-287 (10 μ M) diluted in culture medium containing 0.5% FBS, and stimulating cells with hPAR2 agonists (10 U/mL hTrypsin or 100 μ M SLIGKV-NH₂) during 6 h at 37 °C. Firefly and *Renilla* luciferase activities were measured using the Dual-Glo[®] Luciferase Assay System (Promega) according to the manufacturer's instructions.

Western blot analysis. Cells were transfected with hPAR2 using PEI and seeded in six-well plates (10⁶ cells/well) in complete medium. Twenty-four hours later, cells were starved overnight in serum-free medium. The day after, cells were preincubated with DMSO or I-287 (10 μ M, 30 min), or with PTX (100 ng/mL, 18 h), YM-254890 or G δ 6983 (1 μ M, 30 min; Calbiochem), or CT04 (1 μ g/mL, 6 h; Cytoskeleton, Inc.), and treated with 1 U/mL hTrypsin or 100 μ M SLIGKV-NH₂ for the indicated time. Cells were then washed with ice-cold PBS and lysed in a buffer containing 10 mM Tris buffer (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% SDS, 1% Triton X-100, 10% Glycerol supplemented with protease and phosphatase inhibitors cocktails (Roche). Cell lysates were centrifuged at 20,000 \times g for 30 min at 4 °C. Equal amounts of proteins were separated by SDS-PAGE and transferred onto polyvinylidene fluoride membrane. Proteins were detected using specific antibodies targeting the protein of interest: phospho-FAK (Y397; catalog number: ab12298, 1 : 1000 dilution; Abcam), total-FAK (catalog number: ab40794, 1 : 1000 dilution; Abcam), phospho-ERK1/2 (catalog number 9101; 1 : 1000 dilution; Cell Signaling), and total ERK1/2 (catalog number 9102; 1 : 1000 dilution; Cell Signaling). Western blottings were visualized using enhanced chemiluminescence and detection was performed using a ChemiDoc MP Imaging System (BioRad). Relative densitometry analysis on protein bands was performed using MultiGauge software (Fujifilm). Results were normalized against control bands. Uncropped immunoblots are shown in Supplementary Fig. 13.

Investigation of IL-8 release. HCT 116 or A549 cells were seeded ($2.5\text{--}3 \times 10^5$ cells/well) and grown for 24 h, before transfection with hPAR2 using the X-tremeGENE[™] HP DNA Transfection Reagent (Roche) according to the manufacturer's instructions. Twenty-four hours after, cells were starved overnight before pretreatment with DMSO or I-287 (10 μ M, 30 min), followed by incubation with hTrypsin (1 U/mL) or SLIGKV-NH₂ (100 μ M) for 6 h. TNF- α (10 ng/mL) for 6 h was used as a positive control. Culture medium was collected and the amount of IL-8 secreted into the supernatants was quantified by the DuoSet ELISA human CXCL8/IL-8 immunoassay kit (R&D Systems).

Animals. Adult male C57BL/6J mice weighing 25–30 g (Charles River Laboratories, Canada) were maintained on a 12 h light/dark cycle in groups of three to four per cage. After arrival, mice were acclimatized for a week before any experimental procedure. Water and food were available ad libitum. Maximum efforts have been made to limit the number of animals used and their suffering. All procedures were performed in accordance with the Canadian Council on Animal Care and with the International Association for the Study of Pain guidelines for pain research on animals. Procedures were also approved by the local Animal Care Committee at the Université de Sherbrooke and were part of protocol 242–14.

CFA-induced paw inflammation. To evaluate the in vivo anti-inflammatory activity of 1-287 compound, we used the mouse CFA-induced paw edema model. Briefly, inflammation was induced by the intraplantar injection of 50 μ L of CFA (Calbiochem) to the left hindpaw of mice. CFA was prepared as a 1 : 1 emulsion of paraffin oil and 0.9% saline solution, complemented by the addition of lyophilized bacterial membranes to reach a concentration of 100 μ g/50 μ L (*Mycobacterium butyricum*, BD Difco, Fisher Scientific) as previously described⁷³. Before CFA injection, mice were weighed and the volume of their ipsilateral hindpaws was measured using a plethysmometer (IITC Life Science, Inc.). Each hindpaw was soaked to the medial malleolus and the paw volume determined in microliters. One hour after CFA injection, mice were treated either by vehicle (5% Methylpyrrolidone (Sigma-Aldrich) and 95% of 10% D- α -Tocopherol polyethylene glycol 1000 succinate (TPGS, Sigma-Aldrich)), 1-287 (50 mg/kg), or Ibuprofen (140 mg/kg; Lot #108K1067; Sigma-Aldrich), as a positive control of anti-inflammatory activity. Drugs were administered by gavage in a volume of 500 μ L/30 g of body weight. The dose of Ibuprofen was chosen in accordance to⁷⁴. The paw volume was then evaluated each hour during a 5 h period following CFA injection by an experimenter blind to the treatment.

Statistics and reproducibility. Results are expressed as mean \pm SEM and the number of independent experiments is indicated in the legend of each figure. Data were analyzed in GraphPad Prism 8 Software using Student's *t*-test and analysis of variance followed by Dunnett's or Tukey's post hoc tests for multiple comparisons, performed as appropriate (see figure legends). Significance was determined as $p < 0.05$. Concentration–response curves were fitted in GraphPad Prism using a three-parameter fitting with a standard Hill slope of 1 (agonist) or –1 (inhibitor).

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

All data that support the findings of this study are available from the corresponding author upon request. Source data for the graphs and charts in the main figures are available in Supplementary Data 1.

Received: 5 June 2020; Accepted: 29 October 2020;

Published online: 27 November 2020

References

- Adams, M. N. et al. Structure, function and pathophysiology of protease activated receptors. *Pharm. Ther.* **130**, 248–282 (2011).
- Ramachandran, R., Noorbakhsh, F., Defea, K. & Hollenberg, M. D. Targeting proteinase-activated receptors: therapeutic potential and challenges. *Nat. Rev. Drug Discov.* **11**, 69–86 (2012).
- Nystedt, S., Emilsson, K., Wahlestedt, C. & Sundelin, J. Molecular cloning of a potential proteinase activated receptor. *Proc. Natl Acad. Sci. USA* **91**, 9208–9212 (1994).
- Oikonomopoulou, K. et al. Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more. *Biol. Chem.* **387**, 677–685 (2006).
- Camerer, E., Huang, W. & Coughlin, S. R. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. *Proc. Natl Acad. Sci. USA* **97**, 5255–5260 (2000).
- Zhao, P. et al. Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4. *J. Biol. Chem.* **289**, 27215–27234 (2014).
- Hollenberg, M. D. et al. Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. *Br. J. Pharm.* **171**, 1180–1194 (2014).
- Ramachandran, R. et al. Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2). *J. Biol. Chem.* **286**, 24638–24648 (2011).
- Barry, G. D. et al. Novel agonists and antagonists for human protease activated receptor 2. *J. Med. Chem.* **53**, 7428–7440 (2010).
- Kawabata, A. et al. 2-Furoyl-LIGRL-NH₂, a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent in mice. *Br. J. Pharm.* **144**, 212–219 (2005).
- Yau, M. K. et al. Potent small agonists of protease activated receptor 2. *ACS Med. Chem. Lett.* **7**, 105–110 (2016).
- Jiang, Y. et al. Biased signaling by agonists of protease activated receptor 2. *ACS Chem. Biol.* **12**, 1217–1226 (2017).
- Asokanathan, N. et al. Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E₂ release from human respiratory epithelial cells. *J. Immunol.* **168**, 3577–3585 (2002).
- Steinhoff, M. et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. *Nat. Med.* **6**, 151–158 (2000).
- Bao, Y., Hou, W. & Hua, B. Protease-activated receptor 2 signalling pathways: a role in pain processing. *Expert Opin. Ther. Targets* **18**, 15–27 (2014).
- Steinhoff, M. et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. *J. Neurosci.* **23**, 6176–6180 (2003).
- Chung, H., Ramachandran, R., Hollenberg, M. D. & Muruve, D. A. Proteinase-activated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-beta receptor signaling pathways contributes to renal fibrosis. *J. Biol. Chem.* **288**, 37319–37331 (2013).
- Chung, H. et al. Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors. *Biol. Chem.* **393**, 413–420 (2012).
- Jaber, M. et al. Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer. *Cell Mol. Life Sci.* **71**, 2517–2533 (2014).
- Morris, D. R. et al. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. *Cancer Res.* **66**, 307–314 (2006).
- Yau, M. K., Liu, L. & Fairlie, D. P. Toward drugs for protease-activated receptor 2 (PAR2). *J. Med. Chem.* **56**, 7477–7497 (2013).
- Sayegh, C. E. et al. Bicyclic heteroaryl compounds useful as inhibitors of the PAR-2 signaling pathway. Patent WO2016154075 (2016).
- Sriwai, W. et al. Protein-dependent signaling by protease-activated receptor 2 (PAR2) in smooth muscle: feedback inhibition of RhoA by cAMP-independent PKA. *PLoS ONE* **8**, e66743 (2013).
- McCoy, K. L., Traynelis, S. F. & Hepler, J. R. PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology. *Mol. Pharm.* **77**, 1005–1015 (2010).
- Ayoub, M. A. & Pin, J. P. Interaction of protease-activated receptor 2 with G proteins and beta-arrestin 1 studied by bioluminescence resonance energy transfer. *Front. Endocrinol. (Lausanne)* **4**, 196 (2013).
- Mende, F. et al. Translating biased signaling in the ghrelin receptor system into differential in vivo functions. *Proc. Natl Acad. Sci. USA* **115**, E10255–E10264 (2018).
- Gales, C. et al. Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. *Nat. Struct. Mol. Biol.* **13**, 778–786 (2006).
- Quoyer, J. et al. Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. *Proc. Natl Acad. Sci. USA* **110**, E5088–E5097 (2013).
- Namkung, Y. et al. Functional selectivity profiling of the angiotensin II type 1 receptor using pathway-wide BRET signaling sensors. *Sci. Signal* **11**, <https://doi.org/10.1126/scisignal.aat1631> (2018).
- Takasaki, J. et al. A novel Galphaq11-selective inhibitor. *J. Biol. Chem.* **279**, 47438–47445 (2004).
- Devost, D. et al. Conformational profiling of the AT1 angiotensin II receptor reflects biased agonism, G protein coupling, and cellular context. *J. Biol. Chem.* **292**, 5443–5456 (2017).
- Leduc, M. et al. Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. *J. Pharm. Exp. Ther.* **331**, 297–307 (2009).
- Cheng, Z. et al. Luciferase reporter assay system for deciphering GPCR pathways. *Curr. Chem. Genomics* **4**, 84–91 (2010).
- Namkung, Y. et al. Monitoring G protein-coupled receptor and beta-arrestin trafficking in live cells using enhanced bystander BRET. *Nat. Commun.* **7**, 12178 (2016).
- Thibeault, P. E. & Ramachandran, R. Role of the Helix-8 and C-terminal tail in regulating proteinase activated receptor 2 signaling. *ACS Pharmacol. Transl. Sci.* <https://doi.org/10.1021/acspsci.0c00039> (2020).
- Chikumi, H., Fukuhara, S. & Gutkind, J. S. Regulation of G protein-linked guanine nucleotide exchange factors for Rho, PDZ-RhoGEF, and LARG by tyrosine phosphorylation: evidence of a role for focal adhesion kinase. *J. Biol. Chem.* **277**, 12463–12473 (2002).
- Wojtkiewicz, M. Z., Hempel, D., Sierko, E., Tucker, S. C. & Honn, K. V. Protease-activated receptors (PARs)—biology and role in cancer invasion and metastasis. *Cancer Metastasis Rev.* **34**, 775–796 (2015).
- Arakaki, A. K. S., Pan, W. A. & Trejo, J. GPCRs in cancer: protease-activated receptors, endocytic adaptors and signaling. *Int. J. Mol. Sci.* **19**, <https://doi.org/10.3390/ijms19071886> (2018).
- Kenakin, T. Biased receptor signaling in drug discovery. *Pharm. Rev.* **71**, 267–315 (2019).

40. Zhao, P. et al. Neutrophil elastase activates protease-activated receptor-2 (PAR2) and transient receptor potential Vanilloid 4 (TRPV4) to cause inflammation and pain. *J. Biol. Chem.* **290**, 13875–13887 (2015).
41. Jimenez-Vargas, N. N. et al. Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome. *Proc. Natl Acad. Sci. USA* **115**, E7438–E7447 (2018).
42. Marlo, J. E. et al. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. *Mol. Pharm.* **75**, 577–588 (2009).
43. Mathiesen, J. M. et al. Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. *Mol. Pharm.* **68**, 393–402 (2005).
44. Goupil, E. et al. A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2alpha-mediated Rho/ROCK signaling pathway. *J. Biol. Chem.* **285**, 25624–25636 (2010).
45. Yau, M. K., Lim, J., Liu, L. & Fairlie, D. P. Protease activated receptor 2 (PAR2) modulators: a patent review (2010–2015). *Expert Opin. Ther. Pat.* **26**, 471–483 (2016).
46. Cheng, R. K. Y. et al. Structural insight into allosteric modulation of protease-activated receptor 2. *Nature* **545**, 112–115 (2017).
47. Suen, J. Y. et al. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). *Br. J. Pharm.* **165**, 1413–1423 (2012).
48. Suen, J. Y. et al. Pathway-selective antagonism of proteinase activated receptor 2. *Br. J. Pharm.* **171**, 4112–4124 (2014).
49. Jiang, Y. et al. A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells. *J. Pharm. Exp. Ther.* **364**, 246–257 (2018).
50. Sevigny, L. M. et al. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. *Proc. Natl Acad. Sci. USA* **108**, 8491–8496 (2011).
51. Chikumi, H., Vazquez-Prado, J., Servitja, J. M., Miyazaki, H. & Gutkind, J. S. Potent activation of RhoA by Galpha q and Gq-coupled receptors. *J. Biol. Chem.* **277**, 27130–27134 (2002).
52. Vogt, S., Grosse, R., Schultz, G. & Offermanns, S. Receptor-dependent RhoA activation in G12/G13-deficient cells: genetic evidence for an involvement of Gq/G11. *J. Biol. Chem.* **278**, 28743–28749 (2003).
53. Kennedy, A. J. et al. Structural characterization of agonist binding to protease-activated receptor 2 through mutagenesis and computational modeling. *ACS Pharm. Transl. Sci.* **1**, 119–133 (2018).
54. Klosel, I. et al. Discovery of novel nonpeptidic PAR2 ligands. *ACS Med Chem. Lett.* **11**, 1316–1323 (2020).
55. Jairaman, A., Yamashita, M., Schleimer, R. P., Prakriya, M. & Store-Operated Ca²⁺ release-activated Ca²⁺ channels regulate PAR2-activated Ca²⁺ signaling and cytokine production in airway epithelial cells. *J. Immunol.* **195**, 2122–2133 (2015).
56. Yagi, Y. et al. Involvement of Rho signaling in PAR2-mediated regulation of neutrophil adhesion to lung epithelial cells. *Eur. J. Pharm.* **536**, 19–27 (2006).
57. Ge, L., Shenoy, S. K., Lefkowitz, R. J. & DeFea, K. Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. *J. Biol. Chem.* **279**, 55419–55424 (2004).
58. Zoudilova, M. et al. beta-Arrestins scaffold cofilin with chronophin to direct localized actin filament severing and membrane protrusions downstream of protease-activated receptor-2. *J. Biol. Chem.* **285**, 14318–14329 (2010).
59. Nichols, H. L. et al. beta-Arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway. *Proc. Natl Acad. Sci. USA* **109**, 16660–16665 (2012).
60. Ge, L., Ly, Y., Hollenberg, M. & DeFea, K. A beta-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis. *J. Biol. Chem.* **278**, 34418–34426 (2003).
61. Borensztajn, K. et al. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. *Am. J. Pathol.* **172**, 309–320 (2008).
62. Su, S. et al. Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. *Oncogene* **28**, 3047–3057 (2009).
63. Tsai, C. C., Chou, Y. T. & Fu, H. W. Protease-activated receptor 2 induces migration and promotes Slug-mediated epithelial-mesenchymal transition in lung adenocarcinoma cells. *Biochim. Biophys. Acta Mol. Cell Res* **1866**, 486–503 (2019).
64. Seo, J. H., Seo, J. Y., Chung, H. Y. & Kim, H. Effect of pertussis toxin and herbimycin A on proteinase-activated receptor 2-mediated cyclooxygenase 2 expression in *Helicobacter pylori*-infected gastric epithelial AGS cells. *Yonsei Med. J.* **52**, 522–526 (2011).
65. Kim, K., Lee, J. & Ghil, S. The regulators of G protein signaling RGS16 and RGS18 inhibit protease-activated receptor 2/Gi/o signaling through distinct interactions with Galpha in live cells. *FEBS Lett.* **592**, 3126–3138 (2018).
66. Wallace, J. L. & Devchand, P. R. Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. *Br. J. Pharm.* **145**, 275–282 (2005).
67. El-Gabalawy, H., Guenther, L. C. & Bernstein, C. N. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. *J. Rheumatol. Suppl.* **85**, 2–10 (2010).
68. Beyaert, R. et al. Cancer risk in immune-mediated inflammatory diseases (IMID). *Mol. Cancer* **12**, 98 (2013).
69. Kawai, J. & Hayashizaki, Y. DNA book. *Genome Res.* **13**, 1488–1495 (2003).
70. Ehrlich, A. T. et al. Biased signaling of the mu opioid receptor revealed in native neurons. *iScience* **14**, 47–57 (2019).
71. Parent, J. L., Labrecque, P., Orsini, M. J. & Benovic, J. L. Internalization of the TXA2 receptor alpha and beta isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. *J. Biol. Chem.* **274**, 8941–8948 (1999).
72. Luttrell, L. M. et al. Manifold roles of beta-arrestins in GPCR signaling elucidated with siRNA and CRISPR/Cas9. *Sci. Signal.* **11**, <https://doi.org/10.1126/scisignal.aat7650> (2018).
73. Parent, A. J. et al. Increased anxiety-like behaviors in rats experiencing chronic inflammatory pain. *Behav. Brain Res.* **229**, 160–167 (2012).
74. Wang, C. et al. Wu-tou decoction inhibits chronic inflammatory pain in mice: participation of TRPV1 and TRPA1 ion channels. *Biomed. Res. Int.* **2015**, 328707 (2015).

Acknowledgements

We thank Monique Lagacé for critical reading of the manuscript. The project was supported by an Industry Partnered Collaborative Research (IPCR 136753) Operating Grant to M.B. with an equivalent contribution between Canadian Institutes of Health Research's (CIHR) and the industry partner Vertex Pharmaceuticals. This work was also partially supported by a CIHR grant to L.G. (MOP-123399). M.B. holds a Canada research Chair in Signal Transduction and Molecular Pharmacology.

Author contributions

C.A., L.G., C.S., J.M., and M.B. designed research. C.A. and S.G. performed the biological experiments. C.S., J.M., Y.B., and C.E.S. developed and synthesized I-287 compound. C.L.G., M.S., and F.G. generated and validated BRET-based biosensors. C.A., S.G., L.G., C.S., C.E.S., and M.B. analyzed data. C.A. and M.B. wrote the paper.

Competing interests

M.S. and F.G. were employees of IRIC at the Université de Montréal during their involvement in this work and are now employees of Domain Therapeutics N.A. to which some of the biosensors used in the present study were licensed for commercial purposes. C.S., Y.B., and C.E.S. were employees of Vertex Pharmaceuticals (Canada) during their involvement in this work and are now employees of Paraza Pharma, Inc., AdMare BioInnovations, and Ra Pharmaceuticals, respectively. Y.B. is CSO at AdMare BioInnovations and the Chair of the BOD of Domain Therapeutics. J.A.M. holds stocks of Vertex Pharmaceuticals. C.E.S. holds stocks of UCB. M.B. is the president of Domain Therapeutics SAB. C.S. and C.E.S. are among the inventors who filed a patent application related to the compound I-287. C.L.G. and M.B. are among the inventors who filed patent applications related to the biosensors used in this work. These biosensors were licensed to Domain Therapeutics for commercial use. C.A., S.G., and L.G. have no competing interests to declare.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s42003-020-01453-8>.

Correspondence and requests for materials should be addressed to M.B.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020